Author: Liang, Zhihui; Zhu, Haoru; Wang, Xin; Jing, Bo; Li, Zifan; Xia, Xinyu; Sun, Hongwu; Yang, Yun; Zhang, Weiting; Shi, Li; Zeng, Hao; Sun, Bingbing
Title: Adjuvants for Coronavirus Vaccines Cord-id: bqpe6qkf Document date: 2020_11_6
ID: bqpe6qkf
Snippet: Vaccine development utilizing various platforms is one of the strategies that has been proposed to address the coronavirus disease 2019 (COVID-19) pandemic. Adjuvants are critical components of both subunit and certain inactivated vaccines because they induce specific immune responses that are more robust and long-lasting. A review of the history of coronavirus vaccine development demonstrates that only a few adjuvants, including aluminum salts, emulsions, and TLR agonists, have been formulated
Document: Vaccine development utilizing various platforms is one of the strategies that has been proposed to address the coronavirus disease 2019 (COVID-19) pandemic. Adjuvants are critical components of both subunit and certain inactivated vaccines because they induce specific immune responses that are more robust and long-lasting. A review of the history of coronavirus vaccine development demonstrates that only a few adjuvants, including aluminum salts, emulsions, and TLR agonists, have been formulated for the severe acute respiratory syndrome-associated coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV), and currently the SARS-CoV-2 vaccines in experimental and pre-clinical studies. However, there is still a lack of evidence regarding the effects of the adjuvants tested in coronavirus vaccines. This paper presents an overview of adjuvants that have been formulated in reported coronavirus vaccine studies, which should assist with the design and selection of adjuvants with optimal efficacy and safety profiles for COVID-19 vaccines.
Search related documents:
Co phrase search for related documents- abundant protein and adenovirus vector: 1
- acute respiratory syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and ade trigger: 1, 2, 3
- acute respiratory syndrome and adenovirus vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory syndrome and adjuvant alum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and adjuvant antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and adjuvant development: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome and adjuvant free: 1, 2
- acute respiratory syndrome and adjuvant freund: 1
- acute respiratory syndrome and adjuvant mucosal vaccine: 1, 2, 3
- acute respiratory syndrome and adjuvant selection: 1
- adaptive immunity and ade antibody dependent enhancement: 1
- adaptive immunity and adenovirus vaccine: 1, 2
- adaptive immunity and adjuvant alum: 1
- adaptive immunity and adjuvant antigen: 1, 2
- adaptive immunity and adjuvant development: 1, 2
- adaptive immunity and adjuvant free: 1
Co phrase search for related documents, hyperlinks ordered by date